Javascript verkar inte påslaget? - Vissa delar av Lunds universitets webbplats fungerar inte optimalt utan javascript, kontrollera din webbläsares inställningar.
Du är här

Drosophila deoxyribonucleoside kinase mutants with enhanced ability to phosphorylate purine analogs

  • W. Knecht
  • Elzbieta Rozpedowska
  • C. Le Breton
  • M. Willer
  • Z. Gojkovic
  • Michael Sandrini
  • T. Joergensen
  • L. Hasholt
  • B. Munch-Petersen
  • Jure Piskur
Publiceringsår: 2007
Språk: Engelska
Sidor: 1278-1286
Publikation/Tidskrift/Serie: Gene Therapy
Volym: 14
Nummer: 17
Dokumenttyp: Artikel i tidskrift
Förlag: Nature Publishing Group


Transduced deoxyribonucleoside kinases (dNK) can be used to kill recipient cells in combination with nucleoside prodrugs. The Drosophila melanogaster multisubstrate dNK (Dm-dNK) displays a superior turnover rate and has a great plasticity regarding its substrates. We used directed evolution to create Dm-dNK mutants with increased specificity for several nucleoside analogs (NAs) used as anticancer or antiviral drugs. Four mutants were characterized for the ability to sensitize Escherichia coli toward analogs and for their substrate specificity and kinetic parameters. The mutants had a reduced ability to phosphorylate pyrimidines, while the ability to phosphorylate purine analogs was relatively similar to the wild-type enzyme. We selected two mutants, for expression in the osteosarcoma 143B, the glioblastoma U-87M-G and the breast cancer MCF7 cell lines. The sensitivities of the transduced cell lines in the presence of the NAs fludarabine (F-AraA), cladribine (CdA), vidarabine and cytarabine were compared to the parental cell lines. The sensitivity of 143B cells was increased by 470-fold in the presence of CdA and of U-87M-G cells by 435fold in the presence of F-AraA. We also show that a choice of the selection and screening system plays a crucial role when optimizing suicide genes by directed evolution.


  • Biological Sciences
  • purines
  • nucleoside analogs
  • directed evolution
  • deoxyribonucleoside kinase
  • cancer gene therapy


  • ISSN: 0969-7128

Box 117, 221 00 LUND
Telefon 046-222 00 00 (växel)
Telefax 046-222 47 20
lu [at] lu [dot] se

Fakturaadress: Box 188, 221 00 LUND
Organisationsnummer: 202100-3211
Om webbplatsen